A database of FDA approved therapeutic peptides and proteins
ID | ThPPID | Name | Peptide Sequence | Length | Functional Classification | Disease | Brand | Company | Physical Appearance | Route of Administartion | Category | Target |
---|---|---|---|---|---|---|---|---|---|---|---|---|
1367 | Th1053 | Serum albumin iodonated | MKWVTFISLLFLFSSAYSRG Full view | 600 | IV | Hematological Disorders | Volumex | IsoTex Diagnostics | Colorless to very pale yellow. | Intravenous infusion | Diagnostic Agents | Apolipoprotein E,Serum amyloid A-1 protein,Protein AMBP |
1368 | Th1054 | Infliximab | N.A. Full view | 0 | IIa | Immunological | REMICADE | Centocor Inc | Sterile, white, lyophilized powder, following reconstitution with 10 mL of Sterile Water for Injection, USP, the resulting pH is approximately 7.2. | Intravenous infusion | Antirheumatic Agents, Anti-Inflammatory Agents, Non-Steroidal, Dermatologic Agents, Gastrointestinal Agents and Immunosuppressive Agents | Tumor necrosis factor |
1385 | Th1061 | Trastuzumab | Light chain 1: DIQMT Full view | 1364 | IIa | Cancer | Herceptin | Genentech | Sterile, white to pale yellow, preservative-free lyophilized powder |  Intravenous administration | Antineoplastic Agents | Insulin receptor,Insulin-like growth factor 1 receptor,Insulin-degrading enzyme,HLA class II histocompatibility antigen, DQ alpha 2 chain,HLA class II histocompatibility antigen, DQ beta 1 chain,Retinoblastoma-associated protein,Cathepsin D,Carboxypeptidase E,Neuroendocrine convertase 2,Neuroendocrine convertase 1,Protein NOV homolog,Low-density lipoprotein receptor-related protein 2,Insulin-like growth factor-binding protein 7,Synaptotagmin-like protein 4 |
1389 | Th1062 | Rituximab | Heavy Chain: QVQLQQP Full view | 664 | IIa | Cancer/Immunological | Rituxan | Biogen Idec Inc., and Genentech USA, Inc | Sterile, clear, colorless, preservative-free liquid concentrate |  Intravenous administration | Antineoplastic Agents, Immunologic Factors and Antirheumatic Agents | B-lymphocyte antigen CD20,Low affinity immunoglobulin gamma Fc region receptor III-B,Complement C1r subcomponent,Complement C1q subcomponent subunit A,Complement C1q subcomponent subunit B,Complement C1q subcomponent subunit C,Low affinity immunoglobulin gamma Fc region receptor III-A,Complement C1s subcomponent,High affinity immunoglobulin gamma Fc receptor I,Low affinity immunoglobulin gamma Fc region receptor II-a,Low affinity immunoglobulin gamma Fc region receptor II-b,Low affinity immunoglobulin gamma Fc region receptor II-c, Receptor tyrosine-protein kinase erbB-2,Epidermal growth factor receptor,Complement C1r subcomponent,Complement C1q subcomponent subunit A,Complement C1q subcomponent subunit B,Complement C1q subcomponent subunit C,Complement C1s subcomponent,High affinity immunoglobulin gamma Fc receptor I,Low affinity immunoglobulin gamma Fc region receptor II-a,Low affinity immunoglobulin gamma Fc region receptor II-b,Low affinity immunoglobulin gamma Fc region receptor I |
1398 | Th1063 | Basiliximab | Heavy Chain: QLQQSGT Full view | 657 | IIa | Immunological | Simulect | Novartis | Sterile lyophilisate which is available in 6 mL colorless glass vials and is available in 10 mg and 20 mg strength | intravenous infusion mainly or bolus (if no allergic reactions occurs) | Immunosuppressive Agents | N.A. |
1400 | Th1064 | Muromonab | Heavy Chain: QVQLQQS Full view | 664 | IIa | Immunological | ORTHOCLONE OKT3 STERILE SOLUTION | Centocor Ortho Biotech, L.P. | Sterile Solution is a murine monoclonal antibody to the CD3 antigen of human T cells which functions as an immunosuppressant. | For Intravenous Use Only | Immunologic Factors and Immunosuppressive Agents | N.A. |
1403 | Th1065 | Digoxin Immune Fab (Ovine) | Heavy Chain: EVQLQQS Full view | 438 | IIa | Cardiac | DIGIBIND | Galaxo Smith Kline | Sterile lyophilized powder of antigen binding fragments (Fab) derived from specific antidigoxin antibodies raised in sheep. | Intravenous infusion after reconstitution with Sterile Water for Injection | Antidotes | T-cell surface glycoprotein CD3 delta chain, T-cell surface glycoprotein CD3 epsilon chain, T-cell surface glycoprotein CD3 gamma chain, T-cell surface glycoprotein CD3 zeta chain, Low affinity immunoglobulin gamma Fc region receptor III-B, Complement C1r subcomponent, Complement C1q subcomponent subunit A, Complement C1q subcomponent subunit B, Complement C1q subcomponent subunit C, Low affinity immunoglobulin gamma Fc region receptor III-A, Complement C1s subcomponent, High affinity immunoglobulin gamma Fc receptor I, Low affinity immunoglobulin gamma Fc region receptor II-a, Low affinity immunoglobulin gamma Fc region receptor II-b, Low affinity immunoglobulin gamma Fc region receptor II-c |
1404 | Th1065 | Digoxin Immune Fab (Ovine) | Heavy Chain: EVQLQQS Full view | 438 | IIa | Cardiac | DigiFab |  Protherics Inc | Sterile, purified, lyophilized preparation of digoxin-immune ovine Fab (monovalent) immunoglobulin fragments. | Intravenous administration | Antidotes | T-cell surface glycoprotein CD3 delta chain, T-cell surface glycoprotein CD3 epsilon chain, T-cell surface glycoprotein CD3 gamma chain, T-cell surface glycoprotein CD3 zeta chain, Low affinity immunoglobulin gamma Fc region receptor III-B, Complement C1r subcomponent, Complement C1q subcomponent subunit A, Complement C1q subcomponent subunit B, Complement C1q subcomponent subunit C, Low affinity immunoglobulin gamma Fc region receptor III-A, Complement C1s subcomponent, High affinity immunoglobulin gamma Fc receptor I, Low affinity immunoglobulin gamma Fc region receptor II-a, Low affinity immunoglobulin gamma Fc region receptor II-b, Low affinity immunoglobulin gamma Fc region receptor II-c |
1406 | Th1066 | Ibritumomab | Heavy Chain: QAYLQQS Full view | 652 | IIb | Cancer | Zevalin | Spectrum Pharmaceuticals | Clear, colorless, sterile, pyrogen-free, preservative-free solution that may contain translucent particles. | Intravenous infusion | N.A. | Digoxin |
1409 | Th1067 | Daptomycin | N.A. Full view | 0 | IIa | Infectious | CUBICIN | Cubist Pharmaceuticals, Inc | Sterile, preservative-free, pale yellow to light brown, lyophilized cake containing approx 500 mg of daptomycin | Intravenous(IV) Injection | N.A. | B-lymphocyte antigen CD20,Low affinity immunoglobulin gamma Fc region receptor III-B,Complement C1r subcomponent,Complement C1q subcomponent subunit A,Complement C1q subcomponent subunit B,Complement C1q subcomponent subunit C,Low affinity immunoglobulin gamma Fc region receptor III-A,Complement C1s subcomponent,High affinity immunoglobulin gamma Fc receptor I,Low affinity immunoglobulin gamma Fc region receptor II-a,Low affinity immunoglobulin gamma Fc region receptor II-b,Low affinity immunoglobulin gamma Fc region receptor II-c |
1412 | Th1068 | Tositumomab | Heavy Chain 1: QAYLQ Full view | 1351 | IIb | Cancer | Bexxar | Galaxo Smith Kline | Sterile, pyrogen-free, clear to opalescent, colorless to slightly yellow, preservative-free solution | Intravenous(IV) administration | N.A. | Bacterial outer membrane,Lipoteichoic acid synthesis |
1428 | Th1072 | Streptokinase | MKNYLSFGMFALLFALTFGT Full view | 440 | Ic | Metabolic/Haemetological | Streptase | CSL Behring | Sterile, purified preparation formulated as lypholized powder | Intravenous and intracoronary administration. | Fibrinolytic Agents and Thrombolytic Agents | N.A. |
1431 | Th1073 | Alemtuzumab | Heavy Chain 1: QVQLQ Full view | 2839 | IIa | Cancer | CAMPATH | Genzyme Corporation | Sterile, clear, colorless, isotonic solution (pH 6.8-7.4) | Intravenous infusion | N.A. | N.A. |
1432 | Th1073 | Alemtuzumab | Heavy Chain 1: QVQLQ Full view | 2389 | IIa | Cancer | LEMTRADA | Genzyme Corporation | LEMTRADA is a sterile, clear and colorless to slightly yellow, solution (pH 7.2±0.2) for infusion. | Intravenous infusion | NA | NA |
1434 | Th1074 | Alglucerase | ARPCIPKSFGYSSVVCVCNA Full view | 497 | Ia | Metabolic | Ceredase | Genzyme Corporation | Clear sterile non-pyrogenic solution of alglucerase in a citrate buffered solution | Intravenous injection | Enzyme Replacement Agents | Plasminogen,Proteinase-activated receptor 1 |
1435 | Th1075 | Capromab | N.A. Full view | 0 | IV | Cancer | ProstaScint | Jazz Pharmaceuticals, Inc. | Sterile, pyrogen-free, clear, colorless solution that may contain some translucent particles. | Intravenous injection | Indicators, Reagents and Diagnostic Agents | CAMPATH-1 antigen,Low affinity immunoglobulin gamma Fc region receptor III-B,Complement C1r subcomponent,Complement C1q subcomponent subunit A,Complement C1q subcomponent subunit B,Complement C1q subcomponent subunit C,Low affinity immunoglobulin gamma Fc region receptor III-A,High affinity immunoglobulin gamma Fc receptor I,Low affinity immunoglobulin gamma Fc region receptor II-a,Low affinity immunoglobulin gamma Fc region receptor II-b,Low affinity immunoglobulin gamma Fc region receptor II-c |
1437 | Th1076 | Laronidase | APHLVQVDAARALWPLRRFW Full view | 626 | Ia | Metabolic | ALDURAZYME | Genzyme Corporation | Sterile, nonpyrogenic, colorless to pale yellow, clear to slightly opalescent solution that must be diluted prior to administration in 0.9% Sodium Chloride Injection | Intravenous infusion | Enzyme Replacement Agents | N.A. |
1445 | Th1079 | Serum Albumin | DAHKSEVAHRFKDLGEENFK Full view | 585 | IV | Metabolic/genetic | Albunex | Mallinckrodt; Tyco Healthcare | N.A. | Intravenous infusion | Serum substitutes | N.A. |
1446 | Th1079 | Serum Albumin | DAHKSEVAHRFKDLGEENFK Full view | 585 | IV | Metabolic/genetic | Optison | GE Healthcare | N.A. | Intravenous infusion | Serum substitutes | N.A. |
1449 | Th1081 | Antithymocyte Globulin | N.A. Full view | 0 | IIa | Immunological | Antithymocyte globulin | Pfizer | N.A. | Intravenous infusion | Immunologic Factors and Immunosuppressive Agents | N.A. |
1453 | Th1083 | Coagulation Factor Ix | YNSGKLEEFVQGNLERECME Full view | 415 | Ia | Hematological/Metabolic/genetic | Alprolix | Biogen Idec Inc., and Genentech USA, Inc | Sterile, non-pyrogenic, preservative-free, white to off-white, lyophilized powder to cake for reconstitution with the provided diluent | Intravenous infusion | Coagulants and Thrombotic Agents | N.A. |
1456 | Th1086 | Interferon Alfa-2B, Recombinant | CDLPQTHSLGSRRTLMLLAQ Full view | 165 | Ib | Immunological | INTRON® A | Merck | Powder or solution | Intramuscular, Subcutaneous, Intralesional, or Intravenous injection | Immunosuppressive Agents | Granulocyte colony-stimulating factor receptor,Neutrophil elastase, Coagulation factor X,Coagulation factor XI,Coagulation factor VII,Coagulation factor VIII,Prothrombin,Prolow-density lipoprotein receptor-related protein 1,Vitamin K-dependent gamma-carboxylase, Platelet-derived growth factor receptor beta,Platelet-derived growth factor receptor alpha,Alpha-2-macroglobulin |
1460 | Th1087 | Oxytocin | CYIQNCPLG Full view | 9 | Ib | Hormonal | Pitocin | JHP Pharmaceuticals | Sterile, clear, colorless aqueous solution of synthetic oxytocin | Intravenous infusion | Oxytocics, Anti-tocolytic Agents and Labor Induction Agents | Interferon alpha/beta receptor 2,Interferon alpha/beta receptor 1, Globotriaosylceramide |
1466 | Th1090 | Daclizumab | QVQLVQSGAEVKKPGSSVKV Full view | 674 | IIa | Immunologicals | Zenapax | Roche | Clear, sterile, colorless concentrate for further dilution and intravenous administration | Intravenous injection | Immunosuppressive Agents | Fusion glycoprotein F0,Low affinity immunoglobulin gamma Fc region receptor III-B,Complement C1r subcomponent,Complement C1q subcomponent subunit A,Complement C1q subcomponent subunit B,Complement C1q subcomponent subunit C,Low affinity immunoglobulin gamma Fc region receptor III-A,High affinity immunoglobulin gamma Fc receptor I,Low affinity immunoglobulin gamma Fc region receptor II-a,Low affinity immunoglobulin gamma Fc region receptor II-b,Low affinity immunoglobulin gamma Fc region receptor II-c |
1468 | Th1091 | Bevacizumab | DIQMTQSPSSLSASVGDRVT Full view | 214 | IIa | Cardiac | Avastin | Genentech | Slightly opalescent, colorless to pale brown, sterile, pH 6.2 solution for intravenous infusion | Intravenous infusion | Angiogenesis Inhibitors | Interleukin-2 receptor subunit alpha,Interleukin-2 receptor subunit beta,Low affinity immunoglobulin gamma Fc region receptor III-B,Complement C1r subcomponent,Complement C1q subcomponent subunit A,Complement C1q subcomponent subunit B,Complement C1q subcomponent subunit C,Low affinity immunoglobulin gamma Fc region receptor III-A,High affinity immunoglobulin gamma Fc receptor I,Low affinity immunoglobulin gamma Fc region receptor II-a,Low affinity immunoglobulin gamma Fc region receptor II-b,Low affinity immunoglobulin gamma Fc region receptor II-c |
1476 | Th1096 | Idursulfase | SETQANSTTDALNVLLIIVD Full view | 525 | Ia | Metabolic | Elaprase | SHIRE | Sterile, nonpyrogenic clear to slightly opalescent, colorless solution that must be diluted prior to administration in 0.9% Sodium Chloride Injection, USP | Intravenous infusion | Enzyme Replacement Agents | Dermatan sulfate,Heparan sulfate,Perilipin-3 |
1477 | Th1097 | Alglucosidase Alfa | AHPGRPRAVPTQCDVPPNSR Full view | 882 | Ic | Metabolic | LUMIZYME | Genzyme | Sterile, nonpyrogenic, white to off-white, lyophilized cake or powder for reconstitution with 10.3 Ml Sterile Water for Injection, USP | Intravenous infusion | Enzyme Replacement Agents | Cation-dependent mannose-6-phosphate receptor,Glycogen |
1494 | Th1101 | Galsulfase | SGAGASRPPHLVFLLADDLG Full view | 497 | Ia | Metabolic | Naglazyme | BioMarin | Sterile, nonpyrogenic, colorless to pale yellow, clear to slightly opalescent solution that must be diluted with 0.9% Sodium Chloride Injection, USP, prior to administration | Intravenous infusion | Enzyme Replacement Agents | Dermatan sulfate,Perilipin-3 |
1495 | Th1102 | Abatacept | MHVAQPAVVLASSRGIASFV Full view | 357 | IIa | Immunological | ORENCIA | Bristol-Myers Squibb | Lyophilized powder, supplied as a sterile, white, preservative-free, lyophilized powder for intravenous administration | Intravenous infusion and Subcutaneous injection | Antirheumatic Agents and Immunosuppressive Agents | T-lymphocyte activation antigen CD80,T-lymphocyte activation antigen CD86 |
1500 | Th1103 | Cosyntropin | ACTH(1-24): SYSM Full view | 24 | IV | Hormonal | Cortrosyn | Amphastar Pharmaceuticals | N.A. | Intravenous injection, Intravenous infusion, Intramuscular injection | Hormones and Diagnostic Agents | Adrenocorticotropic hormone receptor |
1502 | Th1105 | Insulin Aspart | A chain: GIVEQCCTSIC Full view | 51 | Ia | Hormonal/Metabolic | NovoLog | Novo Nordisk | Sterile, aqueous, clear, and colorless solution | Subcutaneous injection, Intravenous injection | Hypoglycemic Agents and Antidiabetic Agents | Insulin receptor |
1530 | Th1109 | Nesiritide | SPKMVQGSGCFGRKMDRISS Full view | 32 | Ib | Cardiac | NATRECOR | Scios unit of Johnson & Johnson, | White- to off-white lyophilized powder | Intravenous injection | N.A. | N.A. |
1533 | Th1112 | Natural Alpha Interferon Or Multiferon | Inteferon alpha-1: Full view | 997 | IIa | Cancer/Infectious | Intron/ Roferon-A | N.A. | N.A. | Subcutaneous injection, Intravenous injection, Intramuscular injection | N.A. | N.A. |
1536 | Th1115 | Teicoplanin | N.A. Full view | 0 | IIa | Infectious | Targocid | NPS Pharmaceuticals | Light yellow solid | Intravenous injection, Intramuscular injection | Anti-Bacterial Agents | D-Ala-D-Ala moiety of NAM/NAG peptide subunits of peptidoglycan |
1550 | Th1119 | Tocilizumab | N.A. Full view | 0 | IIa | Immunological | ACTEMRA | Genentech | Sterile, preservative-free solution, colorless to pale yellow liquid, with a pH of about 6.5 | Intravenous infusion, Subcutaneous injection | N.A. | Interleukin-6 receptor subunit alpha |
1560 | Th1121 | Pertuzumab | light chain DIQMTQSP Full view | 664 | IIIc | Cancer | Perjeta | Genentech | Sterile, clear to slightly opalescent, colorless to pale brown liquid | Intravenous infusion | Monoclonal antibodies | Receptor tyrosine-protein kinase erbB-2 |
1584 | Th1125 | Golimumab | N.A. Full view | 0 | IIb | Immunological | Simponi Injection | N.A. | Sterile concentrated solution of the golimumab antibody | Intravenous infusion | Antipsoriatic Agents and Monoclonal antibodies and TNF inhibitor | Tumor necrosis factor |
1596 | Th1126 | Belatacept | MHVAQPAVVLASSRGIASFV Full view | 357 | IIa | Immunological | Nulojix | Bristol-Myers Squibb | Sterile, white or off-white lyophilized powder | Intravenous injection | Antirheumatic Agents and Immunosuppressive Agents | T-lymphocyte activation antigen CD86,T-lymphocyte activation antigen CD80 |
1602 | Th1128 | Velaglucerase Alfa | ARPCIPKSFGYSSVVCVCNA Full view | 497 | Ia | Hormonal | VPRIV | Shire | Sterile, preservative free, lyophilized powder | Intravenous infusion | Enzymes | Glucosylceramidase |
1604 | Th1130 | Brentuximab Vedotin | Heavy chain:QIQLQQSG Full view | 664 | IIb | Cancer | Adcetris | Seattle Genetics | Sterile, white to off-white, preservative-free lyophilized cake or powder in single-use vials. | Intravenous infusion | N.A. | Tumor necrosis factor receptor superfamily member 8 |
1608 | Th1131 | Taliglucerase Alfa | EFARPCIPKSFGYSSVVCVC Full view | 504 | Ia | Hormonal | Elelyso | Pfizer | Sterile, non-pyrogenic, lyophilized product. | Intravenous infusion | Enzymes | Glucocerebroside |
1609 | Th1132 | Belimumab | N.A. Full view | 0 | IIa | Immunological | Benlysta | GlaxoSmithKline | Sterile, white to off-white, preservative-free, lyophilized powder | Intravenous infusion | Monoclonal antibodies | Tumor necrosis factor ligand superfamily member 13B |
1616 | Th1133 | Aflibercept | SDTGRPFVEMYSEIPEIIHM Full view | 431 | Ib | Cancer | Zaltrap | Sanofi and Regeneron Pharmaceuticals, Inc. | Sterile, clear, colorless to pale yellow, non-pyrogenic, preservative-free, solution. | Intravenous infusion | Antineoplastic Agents and Ophthalmics | Vascular endothelial growth factor A,Placenta growth factor,Vascular endothelial growth factor B |
1623 | Th1136 | Glucarpidase | ALAQKRDNVLFQAATDEQPA Full view | 393 | Ic | Hormonal | Voraxaze | BTG International | Sterile, preservative-free, white lyophilized powder in single-use vials | Intravenous injection | Enzymes | Methotrexate |
1636 | Th1142 | Obinutuzumab | N.A. Full view | 0 | IIb | Cancer | Gazyva | Genentech | Sterile, clear, colorless to slightly brown, preservative free liquid concentrate | Intravenous infusion | Antineoplastic Agents | B-lymphocyte antigen CD20 |
1644 | Th1147 | Natalizumab | N.A. Full view | 0 | IIa | Genetic/Immunological | Tysabri | Biogen Idec Inc. | Sterile, colorless, and clear to slightly opalescent concentrate | Intravenous infusion | Immunosuppressive agents | N.A. |
1659 | Th1152 | Drotrecogin alfa | Heavy Chain: LIDGKMT Full view | 402 | Ib | Infectious | Xigris | Eli Lilly and Company | Sterile, lyophilized, white to off-white powder | Intravenous Infusion | Antisepsis | Coagulation factor VIII, V, Plasminogen activator inhibitor 1, Thrombomodulin, Vitamin K-dependent protein S, Ceruloplasmin, Prothrombin, Platelet factor 4, Plasma serine protease inhibitor, Serpin B6, Vitamin K-dependent gamma-carboxylase, Endothelial protein C receptor |
1663 | Th1155 | Urokinase | KPSSPPEELKFQCGQKTLRP Full view | 276 | Ib | Haemetological | Kinlytic | N.A. | Sterile lyophilized white powder | Intravenous infusion | N.A. | Plasminogen,Urokinase plasminogen activator surface receptor, Urokinase-type plasminogen activator, Tissue-type plasminogen activator, Plasminogen activator inhibitor 1, 2, Plasma serine protease inhibitor, Low-density lipoprotein receptor-related protein 2, Suppressor of tumorigenicity 14 protein, Nidogen-1 |
1667 | Th1158 | Aprotinin | RPDFCLEPPYTGPCKARIIR Full view | 58 | IIa | Immunological | Trasylol | Bayer Pharmaceuticals | Clear, colorless, sterile isotonic solution | Intravenous administration | N.A. | Trypsin-1, Chymotrypsinogen B, Plasminogen, Kallikrein-! |
1671 | Th1159 | Gemtuzumab ozogamicin | Light Chain 1: QIVLT Full view | 459 | IIb | Cancer | Mylotarg | Wyeth pharmaceuticals inc | Sterile, white, preservative-free lyophilized powder | Intravenous infusion | Antineoplastic agents and Immunotoxins | Myeloid cell surface antigen CD33, Low affinity immunoglobulin gamma Fc region receptor III-B, Complement C1r subcomponent, Complement C1q subcomponent subunit A, Complement C1q subcomponent subunit B, Complement C1q subcomponent subunit C, Low affinity immunoglobulin gamma Fc region receptor III-A, Complement C1s subcomponent, High affinity immunoglobulin gamma Fc receptor I, Low affinity immunoglobulin gamma Fc region receptor II-a, Low affinity immunoglobulin gamma Fc region receptor II-b, Low affinity immunoglobulin gamma Fc region receptor II-c |